1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylmethyl]-3-(4-methoxy-phenyl)urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylmethyl]-3-(4-methoxy-phenyl)urea
• 英文别名: 1-[[2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]methyl]-3-(4-methoxyphenyl)urea
• 化学式: C₂₂H₂₀N₄O₆
• 分子量: 436.424
• InChiKey: PAILYCYKWFAMGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-(aminomethyl)-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione hydrochloride 、 对甲氧基苯异氰酸酯 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以44%的产率得到1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylmethyl]-3-(4-methoxy-phenyl)urea
  参考文献：
  名称：

  WO2008/27542

  摘要：

  公开号：

文献信息

• [EN] USE OF BIOMARKERS FOR PREDICTING CLINICAL SENSITIVITY TO CANCER TREATMENT<br/>[FR] UTILISATION DE BIOMARQUEURS PERMETTANT DE PRÉDIRE LA SENSIBILITÉ CLINIQUE POUR LE TRAITEMENT DU CANCER
  申请人：CELGENE CORP

  公开号：WO2016057503A1

  公开（公告）日：2016-04-14

  A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to a subject having cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula (I):

  一种识别可能对治疗化合物产生响应的患有癌症的受试者的方法，包括向患有癌症的受试者施用治疗化合物；从受试者获取样本；确定样本中生物标志物的水平；如果受试者样本中的生物标志物水平与生物标志物的参考水平相比发生变化，则诊断该受试者可能对治疗化合物产生响应；其中治疗化合物是一种式（I）的化合物。
• 5-SUBSTITUTED ISOINDOLINE COMPOUNDS
  申请人：CELGENE CORPORATION

  公开号：US20150005303A1

  公开（公告）日：2015-01-01

  This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  本发明涉及5-取代的异吲哚啉化合物，以及其药物可接受的盐，溶剂化物，立体异构体和前药。本发明还揭示了这些化合物的使用方法和制药组合物。
• 5-substituted isoindoline compounds
  申请人：CELGENE CORPORATION

  公开号：EP2749559A1

  公开（公告）日：2014-07-02

  The present invention relates to 5-substituted isoindoline compounds of formula (III) or formula (IV) wherein R10, R11, R13, R14, X and Y are as defined herein; or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof. The present invention also relates to a pharmaceutical composition of the compounds of the invention. The present invention also relates to a compound of the invention for use in treating, managing or preventing disease conditions as disclosed herein.

  本发明涉及式 (III) 的 5-取代异吲哚啉化合物 或式（IV） 其中R10、R11、R13、R14、X和Y如本文所定义；或其药学上可接受的盐、溶液、立体异构体或原药。本发明还涉及本发明化合物的药物组合物。本发明还涉及用于治疗、控制或预防本文所公开的疾病状况的本发明化合物。
• METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES
  申请人：Celgene Corporation

  公开号：EP3925609A1

  公开（公告）日：2021-12-22

  Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of pomalidomide with an anti-CSl antibody.

  本文公开了治疗、预防和/或控制多发性骨髓瘤的方法。具体方法包括服用泊马度胺和抗-CSl抗体。
• Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
  申请人：Celgene Corporation

  公开号：US10034872B2

  公开（公告）日：2018-07-31

  Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of an immunomodulatory compound, e.g., lenalidomide or pomalidomide with an anti-CS1 antibody, e.g., elotuzumab in patients who have received autologous stem cell transplantation.

  本文公开了治疗、预防和/或控制多发性骨髓瘤的方法。具体方法包括在接受了自体干细胞移植的患者中使用免疫调节化合物，如来那度胺或泊马度胺与抗CS1抗体，如艾洛妥珠单抗。